"Drugs, Generic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs whose drug name is not protected by a trademark. They may be manufactured by several companies.
| Descriptor ID |
D016568
|
| MeSH Number(s) |
D26.360
|
| Concept/Terms |
Drugs, Generic- Drugs, Generic
- Drugs, Nonproprietary
- Nonproprietary Drugs
- Generic Drugs
|
Below are MeSH descriptors whose meaning is more general than "Drugs, Generic".
Below are MeSH descriptors whose meaning is more specific than "Drugs, Generic".
This graph shows the total number of publications written about "Drugs, Generic" by people in this website by year, and whether "Drugs, Generic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drugs, Generic" by people in Profiles.
-
Gusovsky AV, Lin CC, Kerber K, Reynolds EL, Callaghan BC, Burke JF. Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications. Neurology. 2024 Nov 26; 103(10):e210029.
-
Choudhry NK, Denberg TD, Qaseem A. Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016 Jan 05; 164(1):41-9.
-
Webster GF, Leyden JJ, Gross JA. Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne. J Drugs Dermatol. 2014 Jun; 13(6):665-70.
-
Blackstone EA, Fuhr JP. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Future Med Chem. 2010 Nov; 2(11):1641-9.
-
Fuhr JP. Biosimilars and follow-on biologics. Expert Rev Pharmacoecon Outcomes Res. 2009 Apr; 9(2):149-50.